Skin Cancer and Melanoma
Philogen S.p.A. focuses heavily on intratumoral and neoadjuvant treatment strategies for basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma, including disease resistant to anti-PD1 immunotherapy and lesions amenable to local injection.
- Basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Advanced melanoma
- Non-melanoma skin cancer
Its clinical work also includes locally advanced, recurrent, and unresectable skin tumors, with interest in both surgical and non-surgical management settings.
Soft Tissue and Bone-Related Sarcoma
The sponsor studies advanced soft tissue sarcoma and unresectable or metastatic sarcoma, particularly after prior systemic treatment, with attention to tumor control in heavily pretreated disease.
- Unresectable soft tissue sarcoma
- Metastatic soft tissue sarcoma
- Advanced or metastatic sarcoma
Research in this area spans progressive disease settings where local tumor-directed and systemic combinations are of interest.
Glioblastoma and Central Nervous System Tumors
Philogen S.p.A. is active in glioblastoma, including newly diagnosed, progressive, and recurrent disease, with a particular emphasis on treatment approaches integrated with standard chemoradiotherapy or other systemic regimens.
- Glioblastoma
- Progressive glioblastoma
- Recurrent glioblastoma
This area reflects a strong interest in difficult-to-treat brain tumors requiring disease control in both first-line and relapse settings.
Solid Tumors and Targeted Oncology
The company investigates a broad range of advanced solid tumors, including colorectal cancer, pancreatic adenocarcinoma, prostate cancer, renal cell carcinoma, breast cancer, and oesophageal cancer, as well as tumors expressing FAP or CAIX.
- Metastatic clear cell renal carcinoma
- Pancreatic adenocarcinoma
- Colorectal carcinoma
- Prostate cancer
Its oncology portfolio also includes molecular imaging and targeted radiopharmaceutical research in selected tumor types.
Inflammatory Disease
Beyond oncology, Philogen S.p.A. studies rheumatoid arthritis, with interest in patients experiencing inflammatory flares despite background DMARD therapy.
- Rheumatoid arthritis
- Inflammatory joint flares
This therapeutic area extends the sponsor’s research activity into autoimmune disease and local treatment of joint inflammation.
